Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Cognitive
A synthetic heptapeptide corresponding to the ACTH(4-7) core sequence with a C-terminal Pro-Gly-Pro extension.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Type
Synthetic peptide (heptapeptide)
Molecular formula
C37H51N9O10S
Molecular weight
813.93 g/mol
CAS number
80714-61-0
Amino acids
7
Sequence
Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
Modification
C-terminal Pro-Gly-Pro tripeptide extension of the ACTH(4-7) core; confers resistance to prolyl endopeptidase degradation; PGP is the principal brain metabolite.
A linear heptapeptide consisting of the ACTH(4-7) core sequence (Met-Glu-His-Phe) extended with a C-terminal Pro-Gly-Pro tripeptide. The Pro-Gly-Pro extension confers resistance to prolyl endopeptidase cleavage relative to the native ACTH(4-10) parent sequence, and the PGP fragment is the predominant brain metabolite identified in distribution studies. In-vitro work has characterized specific, calcium-dependent, reversible binding to a membrane site in rodent brain tissue, consistent with a G-protein-coupled receptor structural context. The methionine residue is oxidation-susceptible, and the histidine and N-terminal residues support copper(II) coordination chemistry studied in neuronal cell models.
Lyophilized
20°C, protected from light and moisture
stable long term.
The methionine residue is oxidation-susceptible; protect from light/air; avoid freeze-thaw.
Reviews
Dergunova LV, Filippenkov IB, Limborska SA, Myasoedov NF. (2021). Med Res Rev
Dergunova LV, et al. (2020). Biochemistry (Moscow)
Levitskaya NG, et al. (2018). Biol Bull
Reviews
Tsai SJ. (2007). Medical Hypotheses
Clinical
Gusev EI, et al. (2018). Zh Nevrol Psikhiatr
Lebedeva IS, et al. (2018). Bull Exp Biol Med
Kurysheva NI, et al. (2001). Zh Nevrol Psikhiatr
Polunin GS, et al. (2000). Vestn Oftalmol
Gusev EI, et al. (1997). Zh Nevrol Psikhiatr
Primary research
Sciacca MFM, Naletova I, Giuffrida ML, Attanasio F. (2022). ACS Chem Neurosci
Sudarkina OY, et al. (2021). Int J Mol Sci
Filippenkov IB, et al. (2020). Genes (Basel)
Dergunova LV, Filippenkov IB, et al. (2018). BMC Genomics
Medvedeva EV, Dmitrieva VG, et al. (2017). Mol Genet Genomics
Medvedeva EV, et al. (2014). BMC Genomics
Manchenko DM, et al. (2012). Neurosci Behav Physiol
Agniullin YaV, et al. (2009). J Mol Neurosci
Shadrina MI, et al. (2007). Neurosci Lett
Dolotov OV, et al. (2006). Brain Res
Dolotov OV, et al. (2006). J Neurochem
Shevchenko KV, et al. (2006). Russ J Bioorg Chem
Eremin KO, et al. (2005). Neurochem Res
Levitskaya NG, et al. (2004). Neurosci Behav Physiol
Kost NV, et al. (2001). Russ J Bioorg Chem
Bashkatova VG, et al. (2001). Brain Res
Adan RAH, et al. (1994). Eur J Pharmacol
Also known as: ACTH(4-7)-Pro-Gly-Pro
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| SemaxThis page | Synthetic peptide (heptapeptide) | 813.93 g/mol | 80714-61-0 |
| Selank | Synthetic heptapeptide (tuftsin analog) | 751.88 g/mol | 129954-34-3 |
| ACTH(4–10) Adamantyl Analog | Synthetic peptide (ACTH fragment analog, 9 residues) | 1032.23 g/mol | — |
| N-Acetyl Semax | Synthetic linear heptapeptide derivative (N-terminal acetylation, C-terminal amidation); structural analog of ACTH(4–10) | 855.0 g/mol | 2920938-90-3 |
| Pinealon | Synthetic linear tripeptide (peptide bioregulator) | ~418.4 g/mol | 175175-23-2 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods